Navigation Links
OM-5 Elite Urodynamics System with EMG

ProductsOM-5 Elite Urodynamics System with EMG
Company GYRUS ACMI
Item OM-5 Elite Urodynamics System with EMG
Features 
  • Seven (7) channels of data > Capable of performing H20 and CO2 cystometry, EMG, LPP, UPP, Pressure Flow Studies, and Uroflowmetry
  • Large 10.5" screen > Easy to use
  • Remote control, touch screen, on-line help, user presets > Easy to use
  • Pre-test mode > On-screen viewing during patient preparation
  • Eight (8) configurations > Choose the model you need
  • Pole, wall, or cart mounts > Space-saving mounting options for the smallest offices
  • Wide printout > Three to seven waveforms and data summary on one strip
  • Multiple transducer inputs > Flexible to accept disposable, reusable, or microtip transducers
Description Advanced diagnostic capabilities combined with ease of use make the OM-5 Series the best product in its class. Ideal for office or hospital-based urodynamics, the OM-5 is a complete system for Uroflowmetry, cystometry, leak point pressure, or urethral pressure profiles. Eight (8) configurations are available which make the OM-5 flexible enough to meet the needs of all clinicians. This version of the OM-5 Elite includes EMG, three H2O channels, remote control, volumetric pump, UroFlow, floppy disk drive, keyboard, and 24 MB hard drive.
Info GYRUS ACMI
Customer Service: (508) 804-2600
Web site: http://www.acmicorp.com

Related medicine products :

1. Vasculight Elite
2. Vasoseal Elite
3. NIR Elite OTW Stent System
4. NIR Elite Monorail Stent System
5. Sandman Elite
6. The Elite™ Premium Shoulder Instrument Systems
7. Apogee Elite Two-in-One Laser System
8. Elite System II
9. USA Series DUR-8 Elite Durable Flexible Ureteroscope System with Primary and Secondary Deflection
10. USA Elite System™ Rotating Continuous Flow Resectoscopes
11. USA Elite System™ MRO™-20 Rigid Percutaneous Nephroscopes
Breaking Medicine Technology:The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8Watson Confirms Filing of Abbreviated New Drug Application for Generic Sanctura XR 28R 29 51761 1Watson Confirms Filing of Abbreviated New Drug Application for Generic Sanctura XR 28R 29 51761 2Menopause Is More Than A Hot Flash 51759 1Menopause Is More Than A Hot Flash 51759 2Menopause Is More Than A Hot Flash 51759 3Menopause Is More Than A Hot Flash 51759 4Intravenous Immune Biologics Will Suffer from the Pending Shift in Coverage from the Medical to the Pharmacy Benefit 51757 1Intravenous Immune Biologics Will Suffer from the Pending Shift in Coverage from the Medical to the Pharmacy Benefit 51757 2Intravenous Immune Biologics Will Suffer from the Pending Shift in Coverage from the Medical to the Pharmacy Benefit 51757 3